A weight-loss supplement sold directly to consumers online has been recalled nationwide after FDA laboratory testing found two undeclared drugs inside the same box. The daytime tablets of Lipofit Extreme Fat Burner 2.0 contained fluoxetine, a prescription antidepressant. The nighttime tablets contained 2,4-dinitrophenol, a substance the FDA describes as a pesticide, dye, wood preservative and herbicide that is not approved for any use in people. Anyone still holding the recalled lot should stop taking it and keep it away from others.
What the FDA found
Ana Salazar Modela Tu Cuerpo Inc., of Davie, Florida, announced the recall on 27 August 2026; the FDA published it on 31 August. It covers one lot, 25M12F, with an expiration date of September 2027. The product is packaged as separate AM and PM tablets, and FDA laboratory analysis found a different undeclared substance in each. The morning tablets contained fluoxetine, the active ingredient in an approved prescription drug used for depression, bulimia and obsessive-compulsive disorder. The evening tablets contained 2,4-dinitrophenol, usually shortened to DNP, which the agency says is illegally marketed as a weight-loss product and is approved for no use at all.
Neither substance may lawfully appear in a dietary supplement, and the FDA classifies the product as an unapproved new drug whose safety and effectiveness have never been established. It was distributed across the United States directly to individual buyers through online sales, and the recall reaches down to the consumer level. The company says it has stopped selling and promoting the product and quarantined the inventory it still controls, and that it had received no reports of adverse events at the time of the announcement.
The agency’s risk statement is unusually long. It lists nausea, vomiting, sweating, dizziness and headaches, along with dangerous heart rhythm problems, rapid heart rate and cardiac arrest that can cause sudden death. It also lists seizures, abnormal bleeding and suicidal thoughts. Longer exposure, the FDA says, carries added risks of damage to the eyes, skin, bone marrow, nervous system and heart, as well as dangerously high body temperature and rapid breathing. Taken alongside certain other medicines, it adds, the risk of a fatal cardiac event is higher still.
Why a tainted fat burner is a particular problem
The two substances create different kinds of hazard. Fluoxetine is a prescription drug precisely because it interacts with a long list of other medicines and needs monitoring when it is started or stopped; someone taking it unknowingly is exposed to every one of those interactions with nobody watching for them. DNP is a different matter again. It raises the body’s metabolic rate by wasting energy as heat rather than storing it, which is why it has been sold for weight loss for a century, and it is notorious in toxicology for how little separates an effect from fatal overheating. A buyer swallowing both, one in the morning and one at night, could not have anticipated either.
That is the recurring lesson of over-the-counter weight-loss products: when one produces an effect strong enough to notice, the reason is often that something pharmacologically active has been added to it. A product bought from a website and shipped straight to a home has no step in its journey where anyone checks what is actually in the tablet.
Several things remain unknown. The notice covers a single lot and does not say how many units were sold, over what period, or whether earlier lots were tested and cleared. It does not state how much fluoxetine or DNP each tablet contained. It does not say whether the FDA tested the product in response to a complaint or as part of routine marketplace surveillance. And the absence of reported adverse events proves little for a product bought online by individuals: reporting is voluntary and passive, and buyers who felt unwell would have had no obvious reason to connect it to a supplement, let alone to file a report.
Sources: Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP), US Food and Drug Administration, company announcement 27 August 2026, published 31 August 2026.
